News & Events

Learn about what's new with CMC Biologics

CMC Biologics and Aptevo Therapeutics Enter into Commercial Manufacturing Agreement for IXINITY®


Bothell, WA and Seattle, WA – August 22, 2017 – CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and Aptevo Therapeutics (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that they have entered into an agreement for the continued commercial manufacture of Aptevo’s factor IX therapeutic, IXINITY® Coagulation Factor IX (Recombinant). 
Follow Us
Join us on LinkedIn Follow us on Twitter